Search research articles
Contact Us
Filters
Showing results (321-330 of 460) with videos related to
Page
of 46
Sort By:
JAMA Dermatology
|
May 26, 2018
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial
Mary Kay Koenig, Cynthia S Bell, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD
|
September 5, 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option
Lawrence A Schachner, Adelaide A Hebert, Nanette Silverberg, et al.
Kidney International
|
September 17, 2005
Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus
Brad H Rovin, Huijuan Song, Lee A Hebert, et al.
The Journal of Clinical Investigation
|
January 1, 1986
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli
F J Waxman, L A Hebert, F G Cosio, et al.
Current Directions in Autoimmunity
|
January 15, 2004
The intricate role of complement component C4 in human systemic lupus erythematosus
Yan Yang, Erwin K Chung, Bi Zhou, et al.
Clinical and Experimental Immunology
|
January 18, 2006
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare
D J Birmingham, K F Gavit, S M McCarty, et al.
American Journal of Clinical Dermatology
|
March 24, 2025
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis
Amy S Paller, Adelaide A Hebert, Mercedes E Gonzalez, et al.
The British Journal of Dermatology
|
June 19, 2007
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial
J M Spergel, M Boguniewicz, A S Paller, et al.
Kidney International
|
July 27, 2007
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares
D J Birmingham, B H Rovin, G Shidham, et al.
Maternal & Child Nutrition
|
March 22, 2024
Before and after study of a national complementary and supplementary feeding programme in Rwanda, 2017-2021
Katharine A Hebert, Emmanuel Nsengiyumva, Christine Kayitesi, et al.
Page
of 46
Search research articles
Search
Showing results (321-330 of 460) with videos related to
Sort By:
Page
of 46
JAMA Dermatology
|
May 26, 2018
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial
Mary Kay Koenig, Cynthia S Bell, Adelaide A Hebert, et al.
Journal of Drugs in Dermatology : JDD
|
September 5, 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option
Lawrence A Schachner, Adelaide A Hebert, Nanette Silverberg, et al.
Kidney International
|
September 17, 2005
Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus
Brad H Rovin, Huijuan Song, Lee A Hebert, et al.
The Journal of Clinical Investigation
|
January 1, 1986
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli
F J Waxman, L A Hebert, F G Cosio, et al.
Current Directions in Autoimmunity
|
January 15, 2004
The intricate role of complement component C4 in human systemic lupus erythematosus
Yan Yang, Erwin K Chung, Bi Zhou, et al.
Clinical and Experimental Immunology
|
January 18, 2006
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare
D J Birmingham, K F Gavit, S M McCarty, et al.
American Journal of Clinical Dermatology
|
March 24, 2025
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis
Amy S Paller, Adelaide A Hebert, Mercedes E Gonzalez, et al.
The British Journal of Dermatology
|
June 19, 2007
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial
J M Spergel, M Boguniewicz, A S Paller, et al.
Kidney International
|
July 27, 2007
Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares
D J Birmingham, B H Rovin, G Shidham, et al.
Maternal & Child Nutrition
|
March 22, 2024
Before and after study of a national complementary and supplementary feeding programme in Rwanda, 2017-2021
Katharine A Hebert, Emmanuel Nsengiyumva, Christine Kayitesi, et al.
Page
of 46